inhaling known salbutamol for three days, Results followed by 10 days of inhaler A, then There were no significant differences between another three days of known salbutamol and the resting baseline values of Vo2, Vco2, RQ, finally 10 days of inhaler B (fig 1) . Inhalation heart rate and mean blood pressure at the end of known salbutamol for three days made it of 13 days of salbutamol compared with 10 difficult for the subject to determine what was days of placebo and there were no significant contained in the subsequent coded inhalers, a differences between day 0 and days 13 or 26 ( sustained increase (7 8%) in Vo, in six norIn conclusion, the thermogenic response to mal subjects when compared with pretreat-acute salbutamol in normal subjects is attenument measurements.4These results should be ated by prolonged use of the drug. It is interpreted with great caution because a unlikely that the increase in resting metabolic placebo group was not included, an essential rate reported in patients with chronic airflow step in the design of this type of study in view limitation' is caused by long term treatment of the variation in indirect calorimetry mea-with f, agonists. Further studies are needed surements.6 on the effects of methyl xanthines on metaIn our study, although the mean values for bolic rate before attributing the higher resting resting Vo, and Vco, at the end of the salbu-Vo, and Vco, in these patients exclusively to tamol period were 8-7% and 7-5% higher the increased work of breathing.
than the values recorded on the first day (table 1), these differences were not significant. This may be partly due to a placebo effect as suggested by the (non-significant) increase in mean resting Vo, and Vco, after the placebo period when compared with mea- 
